Alberta to begin assessing a new colorectal cancer screening strategy using Metabolomic Technologies’ PolypDx™

Metabolomic Technologies Inc. (MTI) today announced the launch of a $1.4 million project that will evaluate a new colorectal cancer screening strategy using PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. The project, called the Canadian Assessment of PolypDx™ (CAP), will engage expert physicians, clinicians, patients and laboratory specialists to assess colorectal cancer screening in 3000 patients in five regions located throughout Alberta.

Read full press release details here.